Alice T Shaw


Affiliation: Harvard University
Country: USA


  1. Drilon A, Ou S, Cho B, Kim D, Lee J, Lin J, et al. Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations. Cancer Discov. 2018;8:1227-1236 pubmed publisher
    ..i>Cancer Discov; 8(10); 1227-36. ©2018 AACR. This article is highlighted in the In This Issue feature, p. 1195. ..
  2. Yoda S, Lin J, Lawrence M, Burke B, Friboulet L, Langenbucher A, et al. Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer. Cancer Discov. 2018;8:714-729 pubmed publisher
    ..i>Cancer Discov; 8(6); 714-29. ©2018 AACR.This article is highlighted in the In This Issue feature, p. 663. ..
  3. Dagogo Jack I, Rooney M, Nagy R, Lin J, Chin E, Ferris L, et al. Molecular Analysis of Plasma from Patients with ROS1-Positive Non-Small Cell Lung Cancer. J Thorac Oncol. 2019;: pubmed publisher
    ..Plasma genotyping captures the spectrum of ROS1 fusions observed in tissue. Plasma genotyping is a promising approach to detecting mutations that drive resistance to ROS1-directed therapies. ..
  4. Shaw A, Gandhi L, Gadgeel S, Riely G, Cetnar J, West H, et al. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. Lancet Oncol. 2016;17:234-242 pubmed publisher
    ..Therefore, alectinib could be a suitable treatment for patients with ALK-positive disease who have progressed on crizotinib. F Hoffmann-La Roche. ..
  5. Lin J, Ritterhouse L, Ali S, Bailey M, Schrock A, Gainor J, et al. ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non-Small Cell Lung Cancer. J Thorac Oncol. 2017;12:872-877 pubmed publisher
    ..ROS1 rearrangements rarely overlap with alterations in EGFR, KRAS, ALK, or other targetable oncogenes in NSCLC. ..
  6. Lin J, Riely G, Shaw A. Targeting ALK: Precision Medicine Takes on Drug Resistance. Cancer Discov. 2017;7:137-155 pubmed publisher
    ..Therapeutic strategies that can successfully overcome, and potentially prevent, these resistance mechanisms will have the greatest impact on patient outcome. Cancer Discov; 7(2); 137-55. ©2017 AACR. ..
  7. Shaw A, Kim T, Crino L, Gridelli C, Kiura K, Liu G, et al. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2017;18:874-886 pubmed publisher
    ..Novartis Pharmaceuticals Corporation. ..
  8. Lin J, Shaw A. Recent Advances in Targeting ROS1 in Lung Cancer. J Thorac Oncol. 2017;12:1611-1625 pubmed publisher
    ..This review discusses the biology and diagnosis of ROS1-rearranged NSCLC, and current and emerging treatment options for this disease. Future challenges in the field are highlighted. ..
  9. Shaw A, Felip E, Bauer T, Besse B, Navarro A, Postel Vinay S, et al. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. Lancet Oncol. 2017;18:1590-1599 pubmed publisher, NCT03052608). Pfizer. ..

More Information


  1. Hsu P, Shaw A. Lung Cancer: A Wily Genetic Opponent. Cell. 2017;169:777-779 pubmed publisher
    ..The studies highlight the prognostic value of copy-number heterogeneity assessment in tumor biopsies and circulating tumor DNA detection in plasma and suggest that tracking the evolution of lung cancers might aid clinical practice. ..